Clinical Implementations of Pharmacogenomics

Program Details

  • Intended Audience: Pharmacists interested in precision medicine.
  • Universal Activity Number: 0012-0000-17-317-H04-P
  • Contact Hours: 2.5
  • Program Fees: $25.00
  • Dates Available: 01/01/2018 to 01/01/2021
  • Activity Type: Knowledge


This course will summarize how to develop a clinical pharmacogenetic service, test and reimburse for pharmacogenetic results, and design electronic and written documentation.


Laboratory Testing in Clinical Pharmacogenetics: How to Choose a Commercial Laboratory

At the completion of this activity, the participant will be able to:

  • Compare and contrast approaches to clinical laboratory testing in pharmacogenomics.
  • Explain practice-based differences between panel-based testing as compared with testing individual genes for pharmacogenetic recommendations.
  • List criteria for evaluating commercial pharmacogenetic testing laboratories.
  • Identify essential information needed when interpreting commercial laboratory reports in pharmacogenetics.

Advancing Clinical Implementation of Pharmacogenetics: Progress, Needs, and Opportunities

At the completion of this activity, the participant will be able to:

  • Summarize current national landscape and trends for clinical pharmacogenetics implementation in various practice settings.
  • Compare approaches to genetic testing and patient care that may be used in clinical implementation.
  • List steps for developing a new clinical pharmacogenetics patient care service.
  • Identify factors that influence the successful development of clinical pharmacogenetics services.

Clinical Laboratory Testing and Reimbursement in Pharmacogenetics

At the completion of this activity, the participant will be able to:

  • Describe laboratory testing and reimbursement models for pharmacogenetic testing.
  • Compare and contrast various strategies and methods for pharmacogenetic testing and reimbursement in clinical practice.
  • Summarize reimbursement challenges in precision medicine and strategies for overcoming these challenges.
  • Determine appropriate use of CPT coding for pharmacogenetic testing.

Electronic and Written Documentation in Clinical Pharmacogenetics: How, When, and Why?

At the completion of this activity, the participant will be able to:

  • Discuss the role of electronic health record in implementing clinical pharmacogenetics.
  • Summarize current initatives to improve integration of genomic data into electronic health record.
  • Identify barriers to implementing changes to the electronic health record in pharmacogenetics implementation and strategies to overcome these barriers in practice.

Disclosure Statement

The following speakers, reviewers, and planning committee members have disclosed that he/she has no relevant financial disclosures. No one else in a position to control content has any financial relationships to disclose.

Mark Dunnenberger, Pharm.D.
Director of Pharmacogenomics, Center for Molecular Medicine
NorthShore University Health System

Kristin Weitzel, Pharm.D., CDE, FAPhA
Associate Director, UF Health Personalized Medicine Program
Director, Continuing Pharmacy Education
Editor-in-Chief, Pharmacy Today
Clinical Professor, Pharmacotherapy and Translational Research
University of Florida

Megan Arwood, Pharm.D., BCPS
Clinical Assistant Professor
Department of Pharmacotherapy and Translational Research
University of Florida

Victoria Pratt Ph.D., FACM
Associate Professor of Clinical Medicine
Director, Pharmacogenomics and Molecular Genetics Laboratories
Indiana University

James Hoffman, Pharm.D.
Associate Member, St. Jude Faculty
Chief Patient Safety Officer
Director, Medication-Use Safety Residency Program
St. Jude Children’s Research Hospital

Schedule of Activities and Requirements for Successful Course Completion

Review all course materials, view recorded lectures, receive a 70% or higher on final exam and complete course evaluation.

Credit Reporting

  • The University of Florida College of Pharmacy will report CPE credit to CPE Monitor and CE Broker when applicable. If you would like a paper statement of credit, you may print it from your NABP e-profile.
  • All pharmacists and pharmacy technicians maintain their own license and/or certification and it is their responsibility to follow up with the Office of Continuing Education at the University of Florida if any CE credit discrepancies are found.
  • It is at the University’s discretion to award or deny credit to a late claiming participant (i.e. after 60 days of the participant engaging in a CPE activity) as it is the University’s CE activity and the provider needs to ensure the requirements necessary for credit are successfully completed.
  • The University may request access to CPE Monitor® if the activity in question occurred within the previous 6 months and with an appropriate reason for access, i.e. power outage, etc.

Program Financial Support

This course received no financial program support.

Computer Requirements

Computer and Internet access are required to complete this course. Course content is provided via Canvas.

The minimum hardware, software, and Internet requirements for Canvas can be found here.


Refund Policy for CE Courses

Privacy and Confidentiality Policy


This course in its entirety is copyrighted by the University of Florida Continuing Pharmacy Education and may not be duplicated or reproduced for any other purpose without specific written permission.

Contact Us

For questions or more information, please contact our office.

ACPE logo

The University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.